HK1166305A1 - 用於治療炎症的組合物及方法 - Google Patents

用於治療炎症的組合物及方法

Info

Publication number
HK1166305A1
HK1166305A1 HK12106889.7A HK12106889A HK1166305A1 HK 1166305 A1 HK1166305 A1 HK 1166305A1 HK 12106889 A HK12106889 A HK 12106889A HK 1166305 A1 HK1166305 A1 HK 1166305A1
Authority
HK
Hong Kong
Prior art keywords
inflammation
compositions
treatment
methods
Prior art date
Application number
HK12106889.7A
Other languages
English (en)
Inventor
Per Gjorstrup
C Eric Schwartz
Original Assignee
A T Resolve Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A T Resolve Srl filed Critical A T Resolve Srl
Publication of HK1166305A1 publication Critical patent/HK1166305A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
HK12106889.7A 2009-04-13 2012-07-12 用於治療炎症的組合物及方法 HK1166305A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16873909P 2009-04-13 2009-04-13
US17480609P 2009-05-01 2009-05-01
PCT/US2010/030813 WO2010120719A1 (en) 2009-04-13 2010-04-13 Compositions and methods for the treatment of inflammation

Publications (1)

Publication Number Publication Date
HK1166305A1 true HK1166305A1 (zh) 2012-10-26

Family

ID=42982804

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12106889.7A HK1166305A1 (zh) 2009-04-13 2012-07-12 用於治療炎症的組合物及方法

Country Status (16)

Country Link
US (2) US8673881B2 (zh)
EP (1) EP2419399B1 (zh)
JP (1) JP5785537B2 (zh)
CN (1) CN104203901A (zh)
AU (1) AU2010236663B2 (zh)
BR (1) BRPI1011325A2 (zh)
CA (1) CA2758586A1 (zh)
CL (1) CL2011002548A1 (zh)
ES (1) ES2576086T3 (zh)
HK (1) HK1166305A1 (zh)
IL (1) IL215592A (zh)
MX (1) MX2011010827A (zh)
NZ (1) NZ596228A (zh)
RU (1) RU2543720C2 (zh)
TW (1) TW201039815A (zh)
WO (1) WO2010120719A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US8900626B2 (en) * 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
RU2497498C2 (ru) * 2012-02-14 2013-11-10 Константин Николаевич Руссков Фармацевтическая композиция для профилактики пролиферативной клеточной реакции "митомицин-о"
PT2887932T (pt) 2012-08-22 2020-08-31 David Rafael Rosenberg Messina Utilização de estatinas para doença periodontal e regeneração óssea
US20150246061A1 (en) * 2012-10-19 2015-09-03 Celus Pharmaceuticals, Inc. Vitamin d analogues for the treatment of a neurological disorder
CA2902232C (en) 2013-02-22 2020-12-29 University Of Southern California Methods for treatment of ophthalmic diseases and disorders
WO2016028800A1 (en) * 2014-08-20 2016-02-25 A.T. Resolve Sarl Treatment of corneal haze
EP3267990A4 (en) 2015-03-10 2018-09-05 ELC Management LLC Methods and compositions for treating skin to resolve inflammation and screening for actives that stimulate pro-resolution pathways
CN105287480B (zh) * 2015-10-28 2019-01-11 西安医学院第一附属医院 Resolvin D1作为抗癫痫药物的应用
WO2018211486A1 (en) * 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
CN107445821A (zh) * 2017-08-11 2017-12-08 上海中医药大学 聚炔酸类衍生物
WO2020101790A2 (en) 2018-09-04 2020-05-22 Minerva Neurosciences, Inc. Methods of using a phenoxypropylamine compound to treat pain
EP4022039B1 (en) * 2019-08-27 2024-04-03 Cellin Technologies Oü Activated mesenchymal stem cells for use in treating limb ischemia
JP2023504205A (ja) * 2019-12-09 2023-02-01 ザ ボード オブ スーパーバイザーズ オブ ルイジアナ ステート ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ 角膜病変の治療のための生体分子
CN110988180A (zh) * 2019-12-19 2020-04-10 山东达因海洋生物制药股份有限公司 一种基于杂质谱的埃索美拉唑镁的有关物质分析方法
WO2023250031A1 (en) * 2022-06-21 2023-12-28 Anida Pharma Inc. Compositions and methods for treating hearing and ocular disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
JP3979783B2 (ja) 1997-07-29 2007-09-19 アルコン ラボラトリーズ インコーポレイテッド ガラクトマンナンポリマー及びホウ酸塩を含む眼科組成物
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
WO2003048148A2 (en) 2001-12-03 2003-06-12 Novozymes A/S Statin-like compounds
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
AU2008301895A1 (en) 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for treating autoimmune diseases
CA2702475A1 (en) * 2007-10-12 2009-04-23 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of ophthalmic conditions
DE102008027146B4 (de) 2008-06-02 2012-01-19 Ing. Erich Pfeiffer Gmbh Austragvorrichtung
US8619544B2 (en) 2008-09-23 2013-12-31 Qualcomm Incorporated Apparatus and method for facilitating transmit diversity for communications
WO2010039531A1 (en) * 2008-09-23 2010-04-08 Resolvyx Pharmaceuticals, Inc. Therapeutic compounds

Also Published As

Publication number Publication date
EP2419399A4 (en) 2012-08-29
BRPI1011325A2 (pt) 2016-03-15
US8673881B2 (en) 2014-03-18
US20120101061A1 (en) 2012-04-26
IL215592A0 (en) 2011-12-29
WO2010120719A1 (en) 2010-10-21
TW201039815A (en) 2010-11-16
CN104203901A (zh) 2014-12-10
MX2011010827A (es) 2012-01-20
RU2011146005A (ru) 2013-05-20
EP2419399B1 (en) 2016-03-23
CA2758586A1 (en) 2010-10-21
JP5785537B2 (ja) 2015-09-30
US9315447B2 (en) 2016-04-19
AU2010236663B2 (en) 2015-08-20
IL215592A (en) 2017-02-28
RU2543720C2 (ru) 2015-03-10
JP2012523459A (ja) 2012-10-04
NZ596228A (en) 2014-01-31
US20140275247A1 (en) 2014-09-18
AU2010236663A1 (en) 2011-11-24
ES2576086T3 (es) 2016-07-05
EP2419399A1 (en) 2012-02-22
CL2011002548A1 (es) 2012-07-20

Similar Documents

Publication Publication Date Title
HRP20190059T1 (hr) Pripravci za liječenje boli i/ili upale
HK1166305A1 (zh) 用於治療炎症的組合物及方法
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
EP2603202A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
IL225471A0 (en) Preparations and methods for the prevention and treatment of cancer
EP2655334A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
IL207752A0 (en) Methods of treating inflammation
WO2011049960A9 (en) Compositions and methods for the treatment of sinonasal disorders
EP2331564A4 (en) PROCESS FOR TREATMENT OF IGNITION
HK1159498A1 (zh) 用於治療癌症的方法和組合物
IL218212A0 (en) Therapeutic methods and compositions
EP2498798A4 (en) COMPOSITIONS AND METHODS OF WOUND TREATMENT
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
EP2558085A4 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER
EP2340027A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
IL214349A0 (en) Compositions and methods for the treatment of cancer
EP2480579A4 (en) METHODS OF TREATING INFLAMMATION
PT2403336E (pt) Composições de tratamento de plantas e métodos para a sua utilização
HK1167101A1 (zh) 用於治療多發性硬化症的組合物及方法
EP2437738A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2411031A4 (en) Methods and compositions for the treatment of cancer
EP2547368A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2461870A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
IL209947A0 (en) Compositions and methods for treating corneal inflammation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210409